Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 61

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 61
---
s did not meet any of the criteria that would preclude equity classification. The Company concluded that the preferred shares were more akin to an equity -typeinstrument than a debt -typeinstrument, therefore the conversion features associated with the convertible preferred shares and PPCs were deemed to be clearly and closely related to the host instrument and were not bifurcated as a derivative under ASC 815. Earnings per Share Basic net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted -averagenumber of common shares outstanding for the period. Diluted loss per common share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the computation for a period in which a net loss is reported or if their effect is anti -dilutive. The Company’s potential common shares consist of warrants, options to purchase common shares and shares issuable upon the conversion of preferred shares and PPCs.

A summary of the potentially dilutive securities that were excluded from diluted net loss per share each year because their effect would be antidilutive are presented as follows:

|                                 |     |  June 30, |     |         |
|                                 |     |      2025 |     |    2024 |
| Share options                   |     |    34,417 |     |  38,873 |
| Warrants (excluding pre-funded) |     | 2,450,454 |     | 575,878 |
| Convertible preferred shares    |     | 1,863,032 |     |       — |
|                                 |     | 4,347,903 |     | 614,751 |

Annex A-11 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Segment Reporting The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company’s tangible assets are held in Switzerland. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company